Over a span of 4 weeks, administeringEGCG/AA@MNs once a week to a mouse model of AD led to significantimprovement in skin lesions and a reduction in epidermal hyperplasia.This was evidenced by notable decreases in serum IgE levels and histaminelevels, along with the inhibition of IFN-γ and Th2-type cytokineproduction, compared with those in the untreated AD group. This evidence concerns the gene IFNG and Alzheimer disease.